Diabetes is one of the most rapidly rising health ailments in the United States, with 1.2 million new cases diagnosed every ...
Reported positive interim Phase 1 results for SPY003, a next-generation anti-IL-23 antibody, demonstrating the molecule was well-tolerated and exhibited an ~85-day half-life supporting quarterly or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback